Authors
Loading...
Cross-sectional study reveals viral non-suppression in nearly 20% of adolescents on dolutegravir-based therapy, highlighting the need for tailored adherence support and multi-month dispensing.
Nait et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: